At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 102 enrolled
Drug / intervention
Secukinumab +1 morebiological
Likely dose
Secukinumab 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Explore Changes in Subcutaneous Adipose Tissue and Modulation of Skin Inflammation After 12 Weeks of Treatment With Secukinumab, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis
In Brief
A Phase 4 clinical trial evaluating Secukinumab and Placebo for Plaque Psoriasis. Completed, enrolled 102 participants across 15 sites.
Detailed Summary
This study provided a comparison of secukinumab to placebo with respect to skin inflammation as measured by skin exams in comparison to skin biopsies, adipose tissue and blood sample analyses.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartApr 2017
Primary CompletionApr 2018
Study CompletionFeb 2019
TodayJul 2026
First PostedFeb 16, 2017
Enrollment StartApr 18, 2017
Primary CompletionApr 25, 2018
Study CompletionFeb 26, 2019
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 9.4 years ago
Interventions
Secukinumabbiological
Secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3, and 4 was followed by monthly dosing up to Week 48
Placebobiological
Placebo s.c. at randomization, Weeks 1, 2, 3, 4, and 8; secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48